$AEON
AEON Biopharma, Inc.

2023 Q4 Form 10-Q Financial Statement

#000155837023018706 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.489M $5.460M
YoY Change 124.14%
% of Gross Profit
Research & Development $6.860M $6.383M
YoY Change -14.63%
% of Gross Profit
Depreciation & Amortization $24.00K $21.00K
YoY Change
% of Gross Profit
Operating Expenses $28.31M -$57.87M $2.021M
YoY Change 1300.83% -11956.59%
Operating Profit $57.87M
YoY Change -11956.61%
Interest Expense -$15.83M $2.582M $2.580M
YoY Change -713.57% 9.04%
% of Operating Profit 4.46%
Other Income/Expense, Net $1.655M -$14.00M
YoY Change -691.13%
Pretax Income -$42.49M $43.88M $721.5K
YoY Change -5989.28% 2234.11%
Income Tax $0.00 $0.00 $629.1K
% Of Pretax Income 0.0% 87.19%
Net Earnings -$42.49M $43.88M $92.39K
YoY Change -46089.83% 2571.3%
Net Earnings / Revenue
Basic Earnings Per Share $1.19
Diluted Earnings Per Share -$1.14 $1.19 $0.00
COMMON SHARES
Basic Shares Outstanding 37.16M 37.16M
Diluted Shares Outstanding 37.16M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.158M $16.18M $67.91K
YoY Change 7495.35% 58174.5%
Cash & Equivalents $5.200M $16.20M $67.91K
Short-Term Investments
Other Short-Term Assets $1.064M $734.0K $41.29K
YoY Change 2476.9% 430.31%
Inventory
Prepaid Expenses $41.29K
Receivables
Other Receivables
Total Short-Term Assets $6.222M $16.91M $109.2K
YoY Change 5598.01% 10076.87% -86.93%
LONG-TERM ASSETS
Property, Plant & Equipment $594.0K $356.0K $431.0K
YoY Change 37.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $279.4M
YoY Change
Other Assets $29.00K $29.00K $0.00
YoY Change
Total Long-Term Assets $623.0K $708.0K $279.4M
YoY Change -99.78% -99.74% 1.18%
TOTAL ASSETS
Total Short-Term Assets $6.222M $16.91M $109.2K
Total Long-Term Assets $623.0K $708.0K $279.4M
Total Assets $6.845M $17.62M $279.5M
YoY Change -97.55% -93.65% 0.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.388M $4.013M $2.621M
YoY Change 29.28% 325.2%
Accrued Expenses $7.761M $7.631M $226.9K
YoY Change 3319.85% 4987.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $150.0K
YoY Change -100.0%
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $13.05M $14.18M $3.881M
YoY Change 236.23% 951.69% 365.02%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $146.8M $125.2M $6.562M
YoY Change 2137.61% 1078.58%
Total Long-Term Liabilities $146.8M $125.2M $6.562M
YoY Change 2137.61% 1078.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.05M $14.18M $3.881M
Total Long-Term Liabilities $146.8M $125.2M $6.562M
Total Liabilities $159.9M $139.4M $10.44M
YoY Change 1431.02% 1064.29% -41.59%
SHAREHOLDERS EQUITY
Retained Earnings -$473.6M -$423.1M -$9.470M
YoY Change 4901.24% 3552.32% -44.17%
Common Stock $4.000K $4.000K $14.00K
YoY Change -71.43%
Preferred Stock
YoY Change
Treasury Stock (at cost) $23.00K
YoY Change
Treasury Stock Shares $0.00 $22.82K
Shareholders Equity -$153.0M -$121.7M -$9.437M
YoY Change
Total Liabilities & Shareholders Equity $6.845M $17.62M $279.5M
YoY Change -97.55% -93.65% 0.92%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q4
OPERATING ACTIVITIES
Net Income -$42.49M $43.88M $92.39K
YoY Change -46089.83% 2571.3%
Depreciation, Depletion And Amortization $24.00K $21.00K
YoY Change
Cash From Operating Activities -$11.02M -$15.06M -$170.3K
YoY Change 6371.69% 6149.38%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $60.43K
YoY Change
Cash From Investing Activities $60.43K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 150.0K
YoY Change
NET CHANGE
Cash From Operating Activities -11.02M -15.06M -170.3K
Cash From Investing Activities 60.43K
Cash From Financing Activities 150.0K
Net Change In Cash -11.02M -15.06M 40.15K
YoY Change -27547.07% -75405.0%
FREE CASH FLOW
Cash From Operating Activities -$11.02M -$15.06M -$170.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138848177
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37159600
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138848177
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138848177
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37159600
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138848177
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138848177
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37159600
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138848177
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
21257708
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138848177
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
dei Entity Central Index Key
EntityCentralIndexKey
0001837607
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138848177
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37159600
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
21257708
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.19
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17993000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10438000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-38016000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-343307000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.19
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5000000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-343307000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.19
CY2023Q3 us-gaap Debt Instrument Measurement Input Extensible List
DebtInstrumentMeasurementInputExtensibleList
http://fasb.org/us-gaap/2022#MeasurementInputDiscountRateMember
CY2023Q3 aeon Change In Amount Of Contingent Consideration Liability
ChangeInAmountOfContingentConsiderationLiability
-69715000
CY2023Q3 aeon Change In Amount Of Contingent Consideration Liability
ChangeInAmountOfContingentConsiderationLiability
-69715000
CY2023Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAccruedLiabilitiesCurrent
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
aeon Minimum Percentage Of Voting For Automatic Conversion Of Convertible Preferred Stock
MinimumPercentageOfVotingForAutomaticConversionOfConvertiblePreferredStock
0.0066
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37159600
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40021
dei Entity Registrant Name
EntityRegistrantName
AEON Biopharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-3940478
dei Entity Address Address Line1
EntityAddressAddressLine1
5 Park Plaza
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1750
dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92614
dei City Area Code
CityAreaCode
949
dei Local Phone Number
LocalPhoneNumber
354-6499
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37159600
us-gaap Financial Designation Predecessor And Successor Fixed List
FinancialDesignationPredecessorAndSuccessorFixedList
Successor
CY2022 us-gaap Financial Designation Predecessor And Successor Fixed List
FinancialDesignationPredecessorAndSuccessorFixedList
Predecessor
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16177000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9746000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
734000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
92000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
16911000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
9838000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
356000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
431000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
323000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
475000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
29000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
34000
CY2023Q3 us-gaap Assets
Assets
17619000
CY2022Q4 us-gaap Assets
Assets
10778000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4013000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7805000
CY2023Q3 aeon Accrued Clinical Trails Expenses Current
AccruedClinicalTrailsExpensesCurrent
5641000
CY2022Q4 aeon Accrued Clinical Trails Expenses Current
AccruedClinicalTrailsExpensesCurrent
2051000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1020000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1112000
CY2023Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
569000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2934000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
740000
CY2023Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
0
CY2022Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
38834000
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
70866000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14177000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
82574000
CY2023Q3 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
0
CY2022Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
23132000
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
60426000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
52000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
242000
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2172000
CY2023Q3 aeon Contingent Consideration Liability
ContingentConsiderationLiability
74505000
CY2023Q3 aeon Forward Purchase Agreement And Derivative Liability
ForwardPurchaseAgreementAndDerivativeLiability
48453000
CY2023Q3 us-gaap Liabilities
Liabilities
139359000
CY2022Q4 us-gaap Liabilities
Liabilities
143242000
CY2023Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
44666035
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
21257708
CY2022Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
141920000
CY2022Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
137949000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
207450050
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37159600
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
138848177
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37159600
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
138825356
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
14000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
362114000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
187348000
CY2023Q3 aeon Subscription Receivables
SubscriptionReceivables
-60710000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-423148000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-474839000
CY2023Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
0
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
22821
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
23000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
142000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-121740000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-287500000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
17087000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-121740000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-270413000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17619000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10778000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1055000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5460000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2436000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9841000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5460000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8171000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1573000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6383000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7477000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19803000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6383000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25225000
CY2023Q3 aeon Change In Amount Of Contingent Consideration Liability
ChangeInAmountOfContingentConsiderationLiability
-69715000
CY2023Q3 aeon Change In Amount Of Contingent Consideration Liability
ChangeInAmountOfContingentConsiderationLiability
-69715000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2628000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
-57872000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
9913000
us-gaap Operating Expenses
OperatingExpenses
29644000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
-57872000
us-gaap Operating Expenses
OperatingExpenses
33396000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2628000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
57872000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9913000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29644000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
57872000
us-gaap Operating Income Loss
OperatingIncomeLoss
-33396000
CY2023Q3 aeon Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
2582000
CY2022Q3 aeon Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
-666000
aeon Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
-3528000
aeon Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
15261000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1593000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1593000
CY2023Q3 aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
4959000
CY2023Q3 aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
15776000
aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
4959000
CY2023Q3 aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
15776000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
186000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
141000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
114000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
186000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2372000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13997000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-525000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8373000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13997000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15403000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5000000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
43875000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10438000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38017000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
43875000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17993000
CY2023Q3 aeon Loss And Comprehensive Loss
LossAndComprehensiveLoss
-5000000
CY2023Q3 aeon Loss And Comprehensive Loss
LossAndComprehensiveLoss
43875000
CY2022Q3 aeon Loss And Comprehensive Loss
LossAndComprehensiveLoss
-10438000
aeon Loss And Comprehensive Loss
LossAndComprehensiveLoss
-38017000
CY2023Q3 aeon Loss And Comprehensive Loss
LossAndComprehensiveLoss
43875000
aeon Loss And Comprehensive Loss
LossAndComprehensiveLoss
-17993000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.19
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138848177
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37159600
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138848177
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138848177
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37159600
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138848177
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-283889000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5000000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
729000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-288159000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-167976000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
43875000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2361000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-121740000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-228228000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10438000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1073000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-237593000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-270413000
us-gaap Net Income Loss
NetIncomeLoss
-38017000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3235000
aeon Stockholders Equity Period Increase Decrease Through Debit Extinguishment Due To Warrant Modification
StockholdersEquityPeriodIncreaseDecreaseThroughDebitExtinguishmentDueToWarrantModification
17036000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-288159000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-167976000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
43875000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2361000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-121740000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-223824000
us-gaap Net Income Loss
NetIncomeLoss
-17993000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4224000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-237593000
us-gaap Profit Loss
ProfitLoss
-38017000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
43875000
us-gaap Profit Loss
ProfitLoss
-17993000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
54000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
36000
us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
331000
us-gaap Share Based Compensation
ShareBasedCompensation
3234000
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2361000
us-gaap Share Based Compensation
ShareBasedCompensation
4224000
aeon Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
-3528000
aeon Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
15261000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1593000
aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
4959000
CY2023Q3 aeon Change In Fair Value Of Forward Purchase Agreement And Derivative
ChangeInFairValueOfForwardPurchaseAgreementAndDerivative
15776000
CY2023Q3 aeon Change In Amount Of Contingent Consideration Liability
ChangeInAmountOfContingentConsiderationLiability
-69715000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-36000
CY2023Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
363000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-248000
CY2023Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3716000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1433000
aeon Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
4736000
CY2023Q3 aeon Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
-1701000
aeon Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
284000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
27000
CY2023Q3 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
6000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
169000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21745000
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15061000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27130000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
297000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-297000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
14000000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
44500000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44500000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7745000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15061000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17073000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5128000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22201000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16200000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-423100000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9700000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-474800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. The </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Company’s most significant estimates relate to the research and development accruals, valuation of common stock and related stock-based compensation, and the fair values of the contingent consideration, forward purchase agreements, in-process research and development, warrant liabilities, convertible notes, among others. Although the Company bases estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments over the carrying values of assets and liabilities, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q3 aeon Third Party Usage Liabilities Current
ThirdPartyUsageLiabilitiesCurrent
91000
CY2022Q4 aeon Third Party Usage Liabilities Current
ThirdPartyUsageLiabilitiesCurrent
202000
CY2023Q3 aeon Remaining Other Accrued Liabilities
RemainingOtherAccruedLiabilities
675000
CY2022Q4 aeon Remaining Other Accrued Liabilities
RemainingOtherAccruedLiabilities
281000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2934000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
740000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to early-stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of its current and any future product candidates, ability to obtain regulatory approval of its current and any future product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients and significant competition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company relies on Daewoong Pharmaceutical Co., Ltd. (“Daewoong”), a South Korean pharmaceutical manufacturer, as an exclusive and sole supplier to manufacture the Company’s source material for product candidates. Any termination or loss of significant rights, including exclusivity, under the Company’s license and supply agreement with Daewoong (the “Daewoong Agreement”) would materially and adversely affect the Company’s commercialization of its products. See Note 7, “Commitments and Contingencies” for a discussion of the Daewoong Agreement.</p>
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
502000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
502000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
146000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
71000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
356000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
431000
us-gaap Legal Fees
LegalFees
1873000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
296000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
257000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17993000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138848177
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10438000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138848177
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38017000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138848177
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
43875000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37159600
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.19
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5000000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138848177
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
43875000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37159600
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.19
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38818536
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
32116244
CY2023Q3 aeon Number Of Shares To Be Received Prior To Merger
NumberOfSharesToBeReceivedPriorToMerger
2.328
CY2023Q3 aeon Changes In Fair Value Of Convertible Notes
ChangesInFairValueOfConvertibleNotes
2600000
aeon Changes In Fair Value Of Convertible Notes
ChangesInFairValueOfConvertibleNotes
-3500000
CY2023Q3 aeon Changes In Fair Value Of Convertible Notes
ChangesInFairValueOfConvertibleNotes
-700000
aeon Changes In Fair Value Of Convertible Notes
ChangesInFairValueOfConvertibleNotes
29300000
CY2022Q4 us-gaap Convertible Debt
ConvertibleDebt
111000000
CY2022Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
131300000
CY2016Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
342011
CY2016Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.3097
CY2016Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
800000
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-15500000
CY2023Q2 aeon Number Of Additional Shares To Be Issued
NumberOfAdditionalSharesToBeIssued
16000000
CY2023Q2 aeon Threshold Increase In Episodic Migraine Contingent Consideration Shares
ThresholdIncreaseInEpisodicMigraineContingentConsiderationShares
11000000
CY2023Q2 aeon Number Of Chronic Migraine Contingent Consideration Shares By Increase In Episodic Migraine Contingent Consideration Shares
NumberOfChronicMigraineContingentConsiderationSharesByIncreaseInEpisodicMigraineContingentConsiderationShares
0
CY2023Q2 aeon Number Of Contingent Consideration Shares To Be Issued Upon Threshold Increase In Episodic Migraine Contingent Consideration Shares
NumberOfContingentConsiderationSharesToBeIssuedUponThresholdIncreaseInEpisodicMigraineContingentConsiderationShares
0
CY2023Q2 aeon Reduction In Number Of Chronic Migraine Contingent Consideration Shares If Product Licenses Given Before Satisfaction Of Issuance Of Shares
ReductionInNumberOfChronicMigraineContingentConsiderationSharesIfProductLicensesGivenBeforeSatisfactionOfIssuanceOfShares
1000000
CY2023Q2 aeon Minimum Number Of Chronic Migraine Contingent Consideration Shares After Reduction
MinimumNumberOfChronicMigraineContingentConsiderationSharesAfterReduction
0
CY2021Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
78000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
292000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
370000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
22000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
348000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
296000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
52000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
323000
CY2023Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P1Y2M12D
CY2023Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.10
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
16000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
53000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
69000
us-gaap Operating Lease Cost
OperatingLeaseCost
153000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
53000
us-gaap Operating Lease Cost
OperatingLeaseCost
210000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
26000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
51000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
74000
us-gaap Operating Lease Payments
OperatingLeasePayments
180000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
51000
us-gaap Operating Lease Payments
OperatingLeasePayments
173000
CY2023Q3 aeon Deferred Underwriting Fee
DeferredUnderwritingFee
1250000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
44666035
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
44666035
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
21257708
CY2022Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
141920000
CY2022Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
137949000
aeon Number Of Votes For Each Share Of Common Stock Into Which Preferred Stock Could Be Converted
NumberOfVotesForEachShareOfCommonStockIntoWhichPreferredStockCouldBeConverted
1
CY2023Q3 us-gaap Preferred Stock Convertible Conversion Ratio
PreferredStockConvertibleConversionRatio
1
CY2023Q3 us-gaap Temporary Equity Liquidation Preference Per Share
TemporaryEquityLiquidationPreferencePerShare
7.3097
aeon Minimum Net Proceeds From Sale Of Common Stock In Underwritten Public Offering For Automatic Conversion Of Convertible Preferred Stock
MinimumNetProceedsFromSaleOfCommonStockInUnderwrittenPublicOfferingForAutomaticConversionOfConvertiblePreferredStock
50000000
aeon Public Offering Price Per Share As Percentage Of Then Effective Per Share
PublicOfferingPricePerShareAsPercentageOfThenEffectivePerShare
0.714286
CY2016Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
342011
CY2016Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.3097
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
207450050
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
138848177
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
138825356
CY2022 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2022 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2023Q3 aeon Number Of Shares To Be Received Prior To Merger
NumberOfSharesToBeReceivedPriorToMerger
2.328
CY2023Q3 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37159600
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
38876675
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
59178609

Files In Submission

Name View Source Status
aeon-20230930_lab.xml Edgar Link unprocessable
aeon-20230930_pre.xml Edgar Link unprocessable
0001558370-23-018706-index-headers.html Edgar Link pending
0001558370-23-018706-index.html Edgar Link pending
0001558370-23-018706.txt Edgar Link pending
0001558370-23-018706-xbrl.zip Edgar Link pending
aeon-20230930.xsd Edgar Link pending
aeon-20230930x10q.htm Edgar Link pending
aeon-20230930xex31d1.htm Edgar Link pending
aeon-20230930xex31d2.htm Edgar Link pending
aeon-20230930xex32d1.htm Edgar Link pending
aeon-20230930xex32d2.htm Edgar Link pending
aeon-20230930_def.xml Edgar Link unprocessable
aeon-20230930_cal.xml Edgar Link unprocessable
aeon-20230930x10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending